Aclarion Technology Demonstrates Potential Beyond Surgical Planning in New Immune-Biomarker Study
Aclarion announced that its Nociscan MRS technology was utilized in an NIH-funded study that won the 2026 ISSLS Best Paper Award. The study, conducted by investigators at the University of Zurich, UCSF, and the REACH Center, used Nociscan’s methodology to measure intradiscal propionic acid in patients with Modic type 1 changes.
Key figures
- Global patient population
- 266 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.